Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study

A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer

NCT01874678 ·Status: COMPLETED ·Phase: NA

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

NCT06456138 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01101334 ·Status: COMPLETED ·Phase: PHASE2

Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer

NCT05965102 ·Status: UNKNOWN ·Phase: PHASE1

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

NCT00154739 ·Status: COMPLETED ·Phase: PHASE2

Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer

NCT00173875 ·Status: COMPLETED ·Phase: PHASE2

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

NCT06657690 ·Status: RECRUITING ·Phase: PHASE2

Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer

NCT00546130 ·Status: UNKNOWN ·Phase: PHASE2

Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC

NCT05027100 ·Status: UNKNOWN ·Phase: NA

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

NCT05896059 ·Status: RECRUITING ·Phase: PHASE2

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

NCT01712217 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

NCT07170293 ·Status: RECRUITING ·Phase: PHASE2

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

NCT01955681 ·Status: COMPLETED

Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients

NCT00569114 ·Status: COMPLETED ·Phase: PHASE1

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

NCT02487316 ·Status: WITHDRAWN ·Phase: PHASE4

SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

NCT04650490 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

NCT01342965 ·Status: COMPLETED ·Phase: PHASE3

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NCT04871997 ·Status: COMPLETED

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

NCT06071013 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

NCT04009317 ·Status: UNKNOWN ·Phase: PHASE3

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NCT05778149 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

NCT00614809 ·Status: UNKNOWN ·Phase: PHASE2

tTF-NGR Randomized Study - STS

NCT05597917 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

NCT06250777 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

NCT06136910 ·Status: RECRUITING ·Phase: PHASE1/PHASE2